ABSTRACT
INTRODUCTION: Infective endocarditis (IE) is a life-threatening illness with a high morbidity and mortality, and with a rise in incidence in patients with prosthetic valves and cardiac devices. Recently the Dutch guidelines of IE prophylaxis have been revised, limiting IE prophylaxis to the highest-risk population. The aim of the present study was to investigate the incidence of IE and its trend between 2008-2013 in a regional hospital in the Netherlands. METHODS: This is an observational descriptive study of all patients who were admitted with IE to the Medical Center of Alkmaar (MCA) from 1 January 2008 to 31 December 2013. RESULTS: A total of 89 patients with IE, including 7 patients (7.9 %) with a cardiac device IE (CDIE), were identified. In 2008 there were 8 patients with IE, this increased to 26 patients in 2013. Patients with a prosthetic valve IE increased from 25 % in 2008 to 34.6 % in 2013. This increase was not seen in patients with CDIE. CONCLUSION: In the MCA we have observed an increase in patients with IE since 2010. This increase was in part attributable to prosthetic valve IE. A larger observational study is needed to investigate the increase of IE in the Netherlands.
ABSTRACT
The indolequinone EO9 demonstrated good preclinical activity but failed to show clinical efficacy against a range of tumours following intravenous drug administration. A significant factor in EO9's failure in the clinic has been attributed to its rapid pharmacokinetic elimination resulting in poor drug delivery to tumours. Intravesical administration of EO9 would circumvent the problem of drug delivery to tumours and the principal objective of this study is to determine whether or not bladder tumours have elevated levels of the enzyme NQO1 (NAD(P)H:quinone oxidoreductase) which plays a key role in activating EO9 under aerobic conditions. Elevated NQO1 levels in human bladder tumour tissue exist in a subset of patients as measured by both immunohistochemical and enzymatic assays. In a panel of human tumour cell lines, EO9 is selectively toxic towards NQO1 rich cell lines under aerobic conditions and potency can be enhanced by reducing extracellular pH. These studies suggest that a subset of bladder cancer patients exist whose tumours possess the appropriate biochemical machinery required to activate EO9. Administration of EO9 in an acidic vehicle could be employed to reduce possible systemic toxicity as any drug absorbed into the blood stream would become relatively inactive due to an increase in pH.
Subject(s)
Antineoplastic Agents/therapeutic use , Aziridines/therapeutic use , Indolequinones , Indoles/therapeutic use , Quinone Reductases/metabolism , Urinary Bladder Neoplasms/drug therapy , Aziridines/pharmacokinetics , Humans , Hydrogen-Ion Concentration , Immunohistochemistry , Indoles/pharmacokinetics , Substrate Specificity , Urinary Bladder/enzymology , Urinary Bladder Neoplasms/enzymologySubject(s)
Antineoplastic Agents/therapeutic use , Neoplasms/therapy , Animals , Clinical Trials as Topic , Enzymes , Genetic Therapy , Humans , Immunotherapy , ProdrugsABSTRACT
BACKGROUND: The complexing of Congo red in two different ligand forms - unimolecular and supramolecular (seven molecules in a micelle) - with eight deca-peptides organized in a b-sheet was tested by computational analysis to identify its dye-binding preferences. Polyphenylananine and polylysine peptides were selected to represent the specific side chain interactions expected to ensure particularly the stabilization of the dye-protein complex. Polyalanine was used to verify the participation of non-specific backbone-derived interactions. MATERIAL AND METHODS: The initial complexes for calculation were constructed by intercalating the dye between the peptides in the middle of the beta-sheet. The long axis of the dye molecule (in the case of unimolecular systems) or the long axis of the ribbon-like micelle (in the case of the supramolecular dye form) was oriented parallel to the peptide backbone. This positioning maximally reduced the exposure of the hydrophobic diphenyl (central dye fragment) to water. In general the complexes of supramolecular Congo red ligands appeared more stable than those formed by individual dye molecules. Specific interactions (electrostatic and/or ring stacking) dominated as binding forces in the case of the single molecule, while non-specific surface adsorption seemed decisive in complexing with the supramolecular ligand. RESULTS: Both the unimolecular and supramolecular versions of the dye ligand were found to be likely to form complexes of sufficient stability with peptides. The low stability of the protein and the gap accessible to penetration in the peptide sheet seem sufficient for supramolecular ligand binding, but the presence of positively charged or hydrophobic amino acids may strengthen binding significantly. CONCLUSIONS: The need for specific interaction makes single-molecule Congo red binding rather unusual as a general amyloid protein ligand. The structural feature of Congo red, which enables specific and common interaction with amyloid proteins, probably derives from the ribbon-like self-assembled form of the dye.
Subject(s)
Amyloid beta-Peptides/metabolism , Computer Simulation , Congo Red/metabolism , Amyloid beta-Peptides/chemistry , Models, Molecular , Protein Binding , Protein ConformationABSTRACT
The "First International Symposium on Genetic Anticancer Agents," which took place in Amsterdam on March 8-9, 2000, served as a forum to review the results of preclinical and clinical gene therapy studies for cancer endeavored to date. Despite the fact that gene therapy was initially conceptualized as an approach for inherited genetic disease, it is currently finding its widest employ for treating neoplastic disorders. In this regard, more than 70% of patients treated to date in human clinical gene therapy protocols have been in the context of anticancer regimens. Of note, the application of gene therapy for cancer has proceeded from the same rational basis as was originally conceptualized for inherited genetic disorders. Specifically, the molecular basis of these disorders is increasingly being understood, therapeutic genes are available, and alternative therapies are often lacking. Most recently, the field of gene therapy has enjoyed the realization of the first incontrovertible evidence of clinical benefit, for hemophilia and cardiovascular disease, in its first 15 years of human application. This recent recognition of the potential power of gene therapy, and the current lack of realizing such ends for neoplastic disease, has led to a reassessment of the field. Such a critical analysis is a necessary step in defining the means to progress the technology toward achieving the potential benefits of gene therapy for cancer.
Subject(s)
Genetic Therapy , Neoplasms/therapy , Clinical Trials as Topic , Humans , Immunotherapy , Prodrugs/therapeutic useABSTRACT
Anticancer drug discovery has changed fundamentally owing to recent progress in basic research. Historically, the discovery of potential new drugs for the treatment of cancer has largely relied on large-scale random screening. Although several useful agents have become available, sometimes after the development of chemical analogues of the original OhitO, this approach has generally been disappointing in terms of the efficacy/toxicity balance. To date, a range of cancer-specific molecular and biological drug targets are available providing opportunities for the design and discovery of specific anti-cancer agents with better tumour selectivity, and therefore less toxicity, than conventional agents. Among the many innovative approaches currently explored in pre-clinical and clinical research and development programs are inhibition of angiogenesis and metastasis, tumour vaccines/immunotherapy and gene therapy approaches. Several promising drug development projects are currently underway in these areas. The advent of innovative anticancer agents also has important consequences for the organisation of new drug development. Traditional drug development methodologies are often not appropriate for agents having completely new modes of action. The design of new drug development templates for such agents therefore has high priority in anti-cancer drug development organisations.
Subject(s)
Antineoplastic Agents , Cancer Vaccines , Genetic Therapy , Immunotherapy , Neoplasms/therapy , Angiogenesis Inhibitors/therapeutic use , Antineoplastic Agents/therapeutic use , Humans , ResearchABSTRACT
Human papillomaviruses (HPV) are present in approximately 95% of all cervical carcinomas and the HPV E6 and E7 genes are continuously expressed in these lesions. There is also circumstantial evidence that often natural immunity against HPV is generated and that this is of influence on HPV-induced lesions. Stimulation of the immune system by proper presentation of relevant HPV antigens might, therefore, lead to a prophylactic or therapeutic immunological intervention for HPV-induced lesions. For this purpose we have expressed the E6 and E7 protein of HPV 16 in an attenuated strain of Salmonella typhimurium (SL3261, aroA mutation), which has been used extensively as a live vector. Live recombinant Salmonella vaccines have the ability to elicit humoral, secretory and cell-mediated immune responses, including cytotoxic T cells, against the heterologous antigens they express. This report describes the construction of recombinant Salmonella strains expressing the HPV 16 E6 and E7 proteins, and the induction of an HPV-16-specific immune response in mice after immunization with these live vectors.
Subject(s)
Bacterial Vaccines/immunology , Papillomaviridae/immunology , Vaccines, Synthetic/immunology , Antibodies, Viral/immunology , Antibody Formation , Genes, Viral/immunology , Recombinant Proteins/immunology , Recombination, Genetic , Salmonella Infections/immunology , Salmonella Infections/prevention & control , Salmonella Phages/immunology , Salmonella typhimurium/genetics , Salmonella typhimurium/virologyABSTRACT
The helper T-cell response to the E7 protein of human papillomavirus type 16 (HPV16) was studied using BALB/c (H-2d) mice. Twenty-two overlapping synthetic peptides spanning the HPV16 E7 protein were split into 6 groups. Mice were sensitized using mixtures of synthetic peptides corresponding to each of the groups. Lymph node cell suspensions were cultured with the corresponding mixture of synthetic peptides that was used for sensitization. Two mixtures induced a proliferative response. Analysis of the individual peptides from these mixtures showed that two (overlapping) peptides induced a proliferative response. This response was mediated by CD4+ cells. The common region of the two peptides was found to be a single epitope, and a minimal epitope was demonstrated (AHYNIVTFCCK). In conclusion, in contrast to others, we demonstrated a helper T-cell response in BALB/c mice. This may be due to the fact that we used synthetic peptides as immunizing agent. The helper T-cell epitopes in HPV16 E7 demonstrated previously are partly overlapping with the (minimal) epitope demonstrated here, underlining the 'public' nature of the epitope.
Subject(s)
Antigens, Viral/immunology , Epitopes/immunology , Oncogene Proteins, Viral/immunology , T-Lymphocytes, Helper-Inducer/immunology , Amino Acid Sequence , Animals , Cells, Cultured , Humans , Lymph Nodes/cytology , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Papillomavirus E7 Proteins , Peptides/chemical synthesis , Peptides/immunologyABSTRACT
The naturally occurring sequence variation of human papillomavirus type 16 (HPV-16) was analysed by direct sequence analysis of the PCR products of the long control region (LCR), the E5 and E7 open reading frames (ORFs), a segment of the L2 ORF overlapping the early viral poly(A) signal and a small segment of the L1 ORF or clinical isolates from Barbados and The Netherlands. Despite the widely different geographical and ethnic origin of the two groups of specimens, sequence analysis revealed relatively few mutational differences. Analysis of the LCR and the E5 ORF appeared to be the minimum requirement for the correct positioning of these variants in the HPV-16 phylogenetic tree. Most of the Barbadian variants appeared to be located at a unique position in the HPV-16 phylogenetic tree, at the internal branch close to the point where the European and Asian branches diverge. In contrast, most of the Dutch samples were located on the European branch.
Subject(s)
Genetic Variation , Papillomaviridae/genetics , Papillomaviridae/isolation & purification , Phylogeny , Polymerase Chain Reaction/methods , Asia , Barbados , Base Sequence , DNA Primers , Ethnicity , Europe , Humans , Molecular Sequence Data , Mutation , Netherlands , Oncogene Proteins, Viral/genetics , Open Reading Frames , Papillomavirus E7 ProteinsABSTRACT
Detection of HPV-DNA in squamous vulvar carcinoma, its prognostic significance, and investigation of the presence of lichen sclerosus near HPV-DNA-positive vulvar carcinomas were the objectives of this study. In 60 samples of squamous vulvar cancer, we looked for HPV-DNA by means of PCR. The same samples were examined for the presence of lichen sclerosus. The possible prognostic significance of the presence of HPV-DNA and lichen sclerosus was studied. Nineteen (32%) of the samples were HPV-DNA positive using PCR. Patients with an HPV-positive tumor had a better prognosis than those with an HPV-negative tumor (P = 0.03). Lichen sclerosus was found in 19 tumor samples, of which 7 had detectable HPV-DNA. Only a minority of vulvar cancers contain HPV-DNA. In contrast to previous statements, near some of these HPV-positive cancers, lichen sclerosus can be found.
Subject(s)
Carcinoma, Squamous Cell/complications , Carcinoma, Squamous Cell/virology , Papillomaviridae/isolation & purification , Skin Diseases/complications , Vulvar Neoplasms/complications , Vulvar Neoplasms/virology , Base Sequence , Carcinoma, Squamous Cell/mortality , DNA, Viral/analysis , Female , Humans , Molecular Probes/genetics , Molecular Sequence Data , Papillomaviridae/genetics , Polymerase Chain Reaction , Prognosis , Survival AnalysisABSTRACT
This case report describes a 78-year old female patient with chronic lymphocytic leukaemia and neurological symptoms due to progressive multifocal leukoencephalopathy (PML). At autopsy the histopathology was characteristic, the involvement of JC virus was established. PML occurs in immunocompromised patients and is caused by infection with JC papova virus. Epidemiology, clinical course, diagnostic procedures with special reference to the use of the polymerase chain reaction, and therapy are briefly reviewed.
Subject(s)
JC Virus/isolation & purification , Leukemia, Lymphocytic, Chronic, B-Cell/complications , Leukoencephalopathy, Progressive Multifocal/microbiology , Aged , Brain/pathology , Female , Humans , Leukoencephalopathy, Progressive Multifocal/complications , Leukoencephalopathy, Progressive Multifocal/pathologyABSTRACT
Escherichia coli isolated from faeces of 54 healthy volunteers who visited Tunisia for eight days were examined. These volunteers participated in a randomized double-blind placebo-controlled study to establish whether ciprofloxacin could prevent travellers' diarrhoea. Escherichia coli strains isolated before travel, during episodes of travellers' diarrhoea, immediately after return and five weeks after return were serotyped and tested for the presence of virulence genes indicating diarrheogenic properties by hybridization with a set of four non-radioactively labelled DNA probes. Subjects receiving ciprofloxacin prophylactically to prevent travellers' diarrhoea were asymptomatic and no Escherichia coli could be cultured shortly after return home. Sixty-four percent of subjects (18/28) who did not receive antibiotic prophylaxis suffered from travellers' diarrhoea. Hybridization tests detected 8 enterotoxigenic Escherichia coli strains producing heat stable toxin, 13 enterotoxigenic strains producing heat labile toxin and 10 strains which produced both heat labile and stable toxin. Of the 31 probe positive strains, 29 (94%) were cultured from 11 volunteers with travellers' diarrhoea. A bacterial cause was thus determined in 61% of the volunteers who experienced travellers' diarrhoea.
Subject(s)
Diarrhea/microbiology , Escherichia coli/isolation & purification , Travel , Adult , Ciprofloxacin/therapeutic use , DNA Probes , Diarrhea/prevention & control , Escherichia coli/classification , Feces/microbiology , Humans , Middle Aged , Serotyping , Time Factors , TunisiaABSTRACT
The successful transfer of the Ti plasmid T region to the plant cell is mediated by its 24 bp border repeats. Processing of the T-region prior to transfer to the plant cell is started at the right border repeat and is stimulated by a transfer enhancer sequence called "overdrive". Left and right border repeats differ somewhat in nucleotide sequence; moreover, the repeats of different Ti and Ri plasmids are slightly different. Our data indicate that these differences do not have a significant influence on border activity. However, the overdrive sequence is essential for the efficient transfer of a T region via an octopine transfer system. Our data suggest that an overdrive sequence must also be present next to the right border repeats of the nopaline Ti plasmid and the agropine of octopine and nopaline Ti plasmids express some differences in T-DNA processing activities. of cotopine and nopaline Ti plasmids express some differences in T-DNA processing activities.Furthermore, we demonstrate that certain pseudo border repeats, sequences that resemble the native 24 bp border repeat and naturally occur within the octopine Ti plasmid T-region, are able to mediate T region transfer to the plant cell, albeit with much reduced efficiency as compared to wild-type border repeats.
ABSTRACT
Early embryos of Patella vulgata have been injected with Lucifer Yellow. No restriction of dye spread was found. We show that later in the development, the larval trochophore stage present evidence of compartments of cell communication. These dye compartments coincide with different presumptive regions.